Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this study is to evaluate the impact of daily tadalafil 5 mg on storage lower urinary tract symptoms (LUTS) during the early postoperative period following Anatomical endoscopic enucleation of prostate in a randomized controlled clinical trial.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Daily tadalafil 5 mg user | Active Comparator | Patients will have daily tadalafil 5 mg for 3 months post AEEP |
|
| Placebo | Placebo Comparator | Omiga 3 for patient |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Tadalafil 5mg (Male) | Drug | Tadalafil 5 mg is a phosphodiesterase type 5 (PDE-5) inhibitor taken orally, commonly prescribed as a once-daily low dose therapy. It works by relaxing smooth muscle and improving blood flow in specific tissues. |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of patients achieving stress urine incontinence at 12 weeks post op, assessed by IPSS score | More Precise Academic Wording:
Important Methodological Note: The International Prostate Symptom Score (IPSS) is primarily designed to assess lower urinary tract symptoms (LUTS) such as:
| 12 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline in IPSS storage subdomain score at 4 weeks , 8weeks , and 12 weeks. Time to micturate freely IPSS total . | 12 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Ali adel Mansour Hageb, GP | Contact | +201109049717 | +967781118703 | Alihajeb42@gmail.com |
| Adel Kurkar Abdallah, Prof Dr | Contact | +201098197880 | kurkar1970@gmail.com |
Not provided
Not provided
Not provided
| Label | URL |
|---|---|
| Pang KH, Ortner G, Yuan Y, Biyani CS, Tokas T. Complications and functional outcomes of endoscopic enucleation of the prostate: a systematic review and meta-analysis of randomized-controlled studies. Cent European J Urol \[Internet\]. 2022 \[cited 2026 Jan | View source |
| Vo LT, Armany D, Chalasani V, Bariol S V., Baskaranathan S, Hossack T, et al. Endoscopic enucleation of the prostate versus transurethral resection of the prostate for benign prostatic hyperplasia: a systematic review and meta-analysis. Prostate Cancer P | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D011470 | Prostatic Hyperplasia |
| ID | Term |
|---|---|
| D011469 | Prostatic Diseases |
| D005832 | Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000068581 | Tadalafil |
| ID | Term |
|---|---|
| D002243 | Carbolines |
| D011725 | Pyridines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
The drug
Not provided
| Omiga 3 | Drug | Giving omiga 3 for patients who are not in tadalafil group |
|
| 4\. Kim TH, Song PH. Anatomical endoscopic enucleation of the prostate for bladder outlet obstruction: a narrative review. Journal of Yeungnam Medical Science \[Internet\]. 2021 Jan 1 \[cited 2026 Jan 3\];39(1):12-7.: | View source |
| Ma J, Liu Z, Wu J, Zhou Z, Zhang X, Cui Y, et al. Role of application of tadalafil 5 mg once-daily (≥6 months) in men with erectile dysfunction from six randomized controlled trials. Transl Androl Urol \[Internet\]. 2020 Jun 1 \[cited 2026 Jan 3\];9(3):14054 | View source |
| Yang J, Jian ZY, Wang J, Zhang G. Phosphodiesterase type-5 inhibitors for erectile dysfunction following nerve-sparing radical prostatectomy: A network meta-analysis. Medicine \[Internet\]. 2021 Feb 26 \[cited 2026 Jan 3\];100(8):e23778. | View source |
| Goh HJ, Sung JM, Lee KH, Jo JK, Kim KN. Efficacy of phosphodiesterase type 5 inhibitors in patients with erectile dysfunction after nerve-sparing radical prostatectomy: a systematic review and meta-analysis. Transl Androl Urol \[Internet\]. 2022 Feb 1 \[cit | View source |
| Kaulback K, Argáez C. Phosphodiesterase Type 5 Inhibitors for Penile Rehabilitation Post Radical Prostatectomy: A Review of Clinical Effectiveness and Guidelines. Phosphodiesterase Type 5 Inhibitors for Penile Rehabilitation Post Radical Prostatectomy: A | View source |
| Gadelha GCA, Júnior AM de C. Phosphodiesterase-5 inhibitors for erectile function rehabilitation in patients undergoing nerve sparing radical prostatectomy: a scoping review. Rev Col Bras Cir \[Internet\]. 2024 \[cited 2026 Jan 3\];51:e20243757 | View source |
| Clavell-Hernández J, Wang R. PDE-5 inhibitors should be used post radical prostatectomy as erection function rehabilitation? Opinion: No. International Brazilian Journal of Urology : official journal of the Brazilian Society of Urology \[Internet\]. 2017 M | View source |
| D052801 |
| Male Urogenital Diseases |
| D026121 |
| Indole Alkaloids |
| D007211 | Indoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006575 | Heterocyclic Compounds, 3-Ring |